Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01459653 · OUTCOME

Percentage of Patients With Each Prophylaxis Decision by Chemotherapy-associated FN Risk

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor · Source last updated 2016-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days

What was measured

Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes. FN: Febrile Neutropenia; EORTC: European Organisation for Research and Treatment of Cancer

Groups in this outcome

EP2006, >20% Chemo-associated FN Risk

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\>20% chemo-associated FN risk)

EP2006, 10-20% Chemo-associated FN Risk

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (10-20% chemo-associated FN risk).

EP2006, <10% Chemo-associated FN Risk

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\<10% chemo-associated FN risk).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EP2006, >20% Chemo-associated FN Risk640
EP2006, 10-20% Chemo-associated FN Risk650
EP2006, <10% Chemo-associated FN Risk154

Reported measurements

Primary prophylaxis: Correctly treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk35.0Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk17.3Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
Primary prophylaxis:Over-treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk13.0Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk6.9Not reportedNot reportedNot reportedNot reported
Secondary prophylaxis: Correctly treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk3.1Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk1.2Not reportedNot reportedNot reportedNot reported
Secondary prophylaxis: Under-treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk9.3Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk8.1Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
Secondary prophylaxis: Over-treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk3.5Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk2.6Not reportedNot reportedNot reportedNot reported
Primary prophylaxis: Under-treated (%)
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006, >20% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
EP2006, 10-20% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
EP2006, <10% Chemo-associated FN Risk0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        35.0
      2. group Id
        OG001
        value
        17.3
      3. group Id
        OG002
        value
        0
    title
    Primary prophylaxis: Correctly treated (%)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        13.0
      3. group Id
        OG002
        value
        6.9
    title
    Primary prophylaxis:Over-treated (%)
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3.1
      3. group Id
        OG002
        value
        1.2
    title
    Secondary prophylaxis: Correctly treated (%)
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        9.3
      2. group Id
        OG001
        value
        8.1
      3. group Id
        OG002
        value
        0
    title
    Secondary prophylaxis: Under-treated (%)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        3.5
      3. group Id
        OG002
        value
        2.6
    title
    Secondary prophylaxis: Over-treated (%)
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
    title
    Primary prophylaxis: Under-treated (%)
denoms
  1. counts
    1. group Id
      OG000
      value
      640
    2. group Id
      OG001
      value
      650
    3. group Id
      OG002
      value
      154
    units
    Participants
description
Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes. FN: Febrile Neutropenia; EORTC: European Organisation for Research and Treatment of Cancer
groups
  1. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\>20% chemo-associated FN risk)
    id
    OG000
    title
    EP2006, >20% Chemo-associated FN Risk
  2. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (10-20% chemo-associated FN risk).
    id
    OG001
    title
    EP2006, 10-20% Chemo-associated FN Risk
  3. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN (\<10% chemo-associated FN risk).
    id
    OG002
    title
    EP2006, <10% Chemo-associated FN Risk
param Type
NUMBER
reporting Status
POSTED
time Frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days
title
Percentage of Patients With Each Prophylaxis Decision by Chemotherapy-associated FN Risk
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice